ENTA ENANTA PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1177648 · Fiscal year ends 09/30
Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.6%
TTM net income YoY16.7%
TTM EPS YoY38.8%
Revenue 3-yr CAGR-7.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-99.0%
Net margin-108.3%
FCF margin-67.9%
EBITDA margin-91.4%
Returns
ROE-94.2%
ROA-24.5%
ROIC (approx.)-106.7%
Asset turnover0.23x
Leverage & solvency
Liabilities / assets70.9%
Debt / equity0.00x
Current ratio3.78x
Interest coverage-4.43x
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-09-30 | FY20252025-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $63.00M | $65.32M |
| R&D expense | $88.55M | $106.74M |
| SG&A expense | $36.84M | $43.93M |
| Operating income | -$62.38M | -$85.35M |
| Interest expense | $14.07M | $7.68M |
| Pretax income | -$68.21M | -$83.55M |
| Income tax | $40,000 | -$1.66M |
| Net income | -$68.25M | -$81.89M |
| EBITDA | -$57.60M | -$80.76M |
| EPS (basic) | -2.35 | -3.84 |
| EPS (diluted) | -2.35 | -3.84 |
| Weighted avg. shares (diluted) | 29.00M | 21.34M |
| Balance sheet | ||
| Cash & equivalents | $20.27M | $32.30M |
| Short-term investments | $174.24M | $156.57M |
| Receivables | $5.86M | $6.88M |
| Current assets | $205.99M | $204.34M |
| PP&E, net | $30.86M | $35.40M |
| Total assets | $275.58M | $280.73M |
| Current liabilities | $54.46M | $48.55M |
| Total liabilities | $195.38M | $216.01M |
| Shareholders' equity | $80.19M | $64.72M |
| Shares outstanding | 29.14M | 21.39M |
| Cash flow statement | ||
| Operating cash flow | -$42.56M | -$19.27M |
| Capital expenditure | $206,000 | $12.90M |
| Free cash flow | -$42.77M | -$32.17M |
| Investing cash flow | -$17.18M | $40.35M |
| Financing cash flow | $47.72M | -$26.62M |
| Depreciation & amortization | $4.78M | $4.59M |
| Stock-based compensation | $14.03M | $18.57M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.